← Back to Search

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED (Reduce Trial)

N/A
Waitlist Available
Research Sponsored by Dunes Eye Consultants
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group

Summary

Purpose: To evaluate the efficacy of vectored thermal pulsation treatment in subjects with a history of dry eye disease currently using a topical immunomodulator medication.

Eligible Conditions
  • Meibomian Gland Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Subjects discontinuing Topical Immunomodulator use

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lipiflow treatment resultsExperimental Treatment1 Intervention
A single thermal vectored pulsation treatment of MGD with 3 month results review of treatment to evaluate objective and subjective response.

Find a Location

Who is running the clinical trial?

Johnson & JohnsonIndustry Sponsor
112 Previous Clinical Trials
163,651 Total Patients Enrolled
Dunes Eye ConsultantsLead Sponsor
~13 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top